Rivaroxaban Tablet
Product Images NDC 70756-006

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 70756-006). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lifestar Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 01)

Chemical structure diagram of rivaroxaban, the active ingredient in the RIVAROXABAN 2.5 mg oral tablet by Lifestar Pharma LLC. The structure shows connected rings and functional groups typical of this anticoagulant molecule.*

FDA Label Image

Image 1 (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 02)

A pharmacokinetic chart showing fold change and 90% confidence intervals for Cmax and AUC parameters of rivaroxaban across various populations, including end-stage renal disease, renal impairment, age groups, body weight categories, and hepatic impairment. The x-axis represents fold change relative to reference values.*

FDA Label Image

Image 2 (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 03)

A forest plot chart showing the fold change and 90% confidence intervals of pharmacokinetic parameters (Cmax and AUC) for rivaroxaban when administered with various interacting drugs. The chart lists combined P-gp and CYP3A inhibitors and inducers, moderate CYP3A inhibitors, and other drugs such as aspirin, atorvastatin, and warfarin, with fold changes plotted relative to rivaroxaban alone on a logarithmic scale from 0.25 to 4.*

FDA Label Image

Image 3 (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 04)

A forest plot comparing the efficacy outcome of Rivaroxaban versus Placebo across different subgroups such as age, sex, region, weight, eGFR, MI history, stroke history, history of prior heart failure, baseline diabetes, and PAD. The plot displays hazard ratios (HR) with 95% confidence intervals to indicate favoritism towards Rivaroxaban or Placebo for the primary efficacy outcome of composite stroke, MI, or cardiovascular death.*

FDA Label Image

Image 4 (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 05)

A cumulative incidence rate line graph comparing rivaroxaban tablets and placebo over days from randomization up to 1095 days. The y-axis shows cumulative incidence percentage, and the x-axis shows days. The graph includes subject counts at risk for both groups at various time points and reports a hazard ratio of 0.74 (95% CI: 0.65-0.86) favoring rivaroxaban.*

FDA Label Image

Iamge 5 (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 06)

A line graph illustrating the cumulative incidence rate (%) over time (days from randomization) comparing treatment groups of rivaroxaban and placebo. The graph includes a legend, a hazard ratio comparison (0.85 with 95% CI 0.75 to 0.96), and a table showing the number of subjects at risk at various time points for each group.*

FDA Label Image

Image 6 (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 07)

A forest plot comparing the primary efficacy outcome rates of rivaroxaban versus placebo across subgroups based on age, sex, weight, eGFR, diabetes status, CAD, randomization strata, clopidogrel use, history of revascularization, and critical limb ischemia categories. The plot displays hazard ratios (HR) with 95% confidence intervals (CI), showing effect sizes and direction favoring either rivaroxaban or placebo.*

FDA Label Image

2.5 mg 60s (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 08)

Rivaroxaban Tablets USP 2.5 mg oral tablets label for a bottle containing 60 tablets. Manufactured by Lifestar Pharma LLC, this prescription medication label instructs pharmacists to dispense the medication guide separately and includes storage and dosage information. The label includes the product's NDC 70756-006-60 and states it is produced in India.*

FDA Label Image

2.5 mg 180s (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 09)

Rivaroxaban Tablets USP 2.5 mg oral tablets label from Lifestar Pharma LLC. The package contains 180 tablets. It includes dispensing instructions, storage conditions, manufacturer information (Lifestar Pharma LLC, Mahwah, NJ), and medication guide reference with a QR code for more information. The product is identified by NDC 70756-006-81.*

FDA Label Image

2.5 mg 1000s (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 10)

Rivaroxaban Tablets USP 2.5 mg oral tablets packaging label from Lifestar Pharma LLC. The label indicates 1000 tablets per container, including instructions to dispense the Medication Guide separately. Storage and usage guidance are provided along with manufacturer and product origin information.*

FDA Label Image

2.5 mg Carton (0438bd24 Fd5f 476b A7e8 Eeab15f3551b 11)

Rivaroxaban Tablets USP 2.5 mg packaging label for oral tablets by Lifestar Pharma LLC, containing 100 tablets in 10 blister strips of 10 tablets each. The label includes storage instructions, usage warnings, and a QR code for the medication guide. It specifies 'Package Not Child Resistant' and is for hospital use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.